<DOC>
	<DOCNO>NCT02194699</DOCNO>
	<brief_summary>A 52-Week , Multicentre , Randomized , Double-Blind , Parallel Group , Placebo Controlled , Phase 3 Study Evaluate Efficacy Safety Tralokinumab Adults Adolescents Asthma Inadequately Controlled Inhaled Corticosteroid Plus Long-Acting β2-Agonist</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Efficacy Safety Tralokinumab Adults Adolescents With Uncontrolled Asthma</brief_title>
	<detailed_description>This randomize , double-blind , parallel group , placebo-controlled study design evaluate efficacy safety tralokinumab administer subcutaneously subject uncontrolled asthma inhale corticosteroid plus long-acting β2-agonist history asthma exacerbation . Approximately 770 subject randomize globally . Subjects receive tralokinumab , placebo , administer via subcutaneous injection study site , 52-week treatment period .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age 12 75 2 . Documented physiciandiagnosed asthma . 3 . Documented treatment ICS total daily dose correspond ≥500μg fluticasone propionate dry powder formulation equivalent ) LABA 4 . Morning preBD FEV1 value ≥40 &lt; 80 % value ( &lt; 90 % patient 12 17 year age ) PNV . 5 . PostBD reversibility ≥12 % ≥200 mL FEV1 6 . ACQ6 score ≥1.5 1 . Pulmonary disease asthma 2 . History anaphylaxis follow biologic therapy 3 . Hepatitis B , C HIV 4 . Pregnant breastfeed 5 . History cancer 6 . Current tobacco smoke history tobacco smoke ≥ 10 packyears 7 . Previous receipt tralokinumab</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>